

Erratum

Correction

Huang E, Jordan SC: Immunoglobulin G–degrading enzyme of *Streptococcus pyogenes* (IdeS), desensitization, and the kidney allocation system. *Clin J Am Soc Nephrol* 13: 799–801, 2018.

Because of author error, a correction has been issued for the above referenced article. The authors and editors have determined that the disclosures provided by Stanley Jordan at the time of initial publication were incomplete and not aligned with the disclosure policy

for the journal. The disclosures as provided in the original article are included below, as well as the corrected disclosures for the authors.

Published online ahead of print. Publication date available at www.cjasn.org.

See related editorial, “*CJASN* and Disclosure of Conflicts of Interest,” and Errata on pages 785–786 and 907, 909, and 910, respectively.

Table 1. Corrected disclosures (corrections are bolded)

Author	Original Disclosures	Corrected Disclosures
Edmund Huang Stanley C. Jordan	E.H. has no disclosures to report. S.C.J. received grant support from Hansa Medical and is a consultant for Hansa Medical.	E.H. has no disclosures to report. S.C.J. reports grants from Hansa Medical, during the conduct of the study; grants and personal fees from Hansa Medical; grants, personal fees, and other from CSL Behring, grants and personal fees from Vitaeris; and grants from Genentech, outside the submitted work. In addition, Dr. Jordan has a patent Imlifidase + Rituximab for Desensitization pending, a patent anti-IL-6 for treatment of ABMR pending, and a patent C1INH for prevention of DGF pending.